GFAP and Alzheimer disease: The combination of decreasing Aß42/40 and increasing p‐tau181 and GFAP therefore seems promising for the identification and prediction of AD pathology even in early stages such as subjective cognitive decline (SCD) or mild cognitive impairment (MCI).